DK1011648T4 - Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer - Google Patents

Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer

Info

Publication number
DK1011648T4
DK1011648T4 DK98942057T DK98942057T DK1011648T4 DK 1011648 T4 DK1011648 T4 DK 1011648T4 DK 98942057 T DK98942057 T DK 98942057T DK 98942057 T DK98942057 T DK 98942057T DK 1011648 T4 DK1011648 T4 DK 1011648T4
Authority
DK
Denmark
Prior art keywords
tyrosine kinase
kinase inhibitor
prostate cancer
combination
chemical castration
Prior art date
Application number
DK98942057T
Other languages
Danish (da)
English (en)
Other versions
DK1011648T3 (da
Inventor
Jeffry L Vaught
Craig A Dionne
John Isaacs
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22000842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1011648(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of DK1011648T3 publication Critical patent/DK1011648T3/da
Application granted granted Critical
Publication of DK1011648T4 publication Critical patent/DK1011648T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
DK98942057T 1997-08-15 1998-08-13 Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer DK1011648T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5589197P 1997-08-15 1997-08-15
PCT/US1998/016849 WO1999008668A2 (fr) 1997-08-15 1998-08-13 Inhibiteur de tyrosine kinase combine a une castration chimique pour traiter un cancer de la prostate

Publications (2)

Publication Number Publication Date
DK1011648T3 DK1011648T3 (da) 2001-12-27
DK1011648T4 true DK1011648T4 (da) 2005-10-24

Family

ID=22000842

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98942057T DK1011648T4 (da) 1997-08-15 1998-08-13 Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer

Country Status (22)

Country Link
US (1) US5985877A (fr)
EP (1) EP1011648B2 (fr)
JP (1) JP2001515032A (fr)
KR (1) KR100612161B1 (fr)
CN (1) CN1147317C (fr)
AT (1) ATE208210T1 (fr)
AU (1) AU737092B2 (fr)
BR (1) BR9812122A (fr)
CA (1) CA2299471C (fr)
CZ (1) CZ297198B6 (fr)
DE (1) DE69802422T3 (fr)
DK (1) DK1011648T4 (fr)
EA (1) EA002525B1 (fr)
ES (1) ES2163293T5 (fr)
HU (1) HUP0003194A3 (fr)
NO (1) NO325526B1 (fr)
NZ (2) NZ502646A (fr)
PL (1) PL193375B1 (fr)
PT (1) PT1011648E (fr)
TR (1) TR200000415T2 (fr)
UA (1) UA61970C2 (fr)
WO (1) WO1999008668A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136079A4 (fr) * 1998-10-08 2004-09-22 Takeda Chemical Industries Ltd Agents destines a retarder le passage d'un cancer hormono-dependant a un cancer hormono-independant
GB0007371D0 (en) * 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020169154A1 (en) * 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
EP1385546A1 (fr) * 2001-05-08 2004-02-04 MERCK PATENT GmbH Therapie combinee utilisant des anticorps anti-egfr et des agents anti-hormonaux
SE0101697D0 (sv) * 2001-05-14 2001-05-14 Astrazeneca Ab Pharmaceutical combination
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
ATE498408T1 (de) * 2001-08-10 2011-03-15 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
JP4319908B2 (ja) * 2001-08-24 2009-08-26 ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
EP2272566A3 (fr) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation d'anticorps
CA2585717A1 (fr) 2004-10-27 2006-05-04 Medimmune Inc. Modulation d'une specificite d'anticorps par adaptation sur mesure de son affinite a un antigene apparente
CA2602035C (fr) 2005-03-18 2015-06-16 Medimmune, Inc. Rearrangement de l'infrastructure d'anticorps
ATE502954T1 (de) 2005-06-14 2011-04-15 Protox Therapeutics Inc Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
AP2008004569A0 (en) * 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
CA2682292A1 (fr) 2007-03-30 2008-10-09 Medimmune, Llc Formulation aqueuse comportant un anticorps anti-interferon alpha humain
US20090130195A1 (en) * 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CA2887129A1 (fr) 2012-10-09 2014-04-17 Igenica, Inc. Anticorps anti-c16orf54 et leurs methodes d'utilisation
SG11201509982UA (fr) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
JP6800853B2 (ja) 2014-12-11 2020-12-16 ピエール、ファーブル、メディカマン 抗ｃ１０ｏｒｆ５４抗体およびその使用
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
US10736972B2 (en) 2015-05-29 2020-08-11 Memorial Sloan Kettering Cancer Center Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
EP3383908A1 (fr) 2015-12-02 2018-10-10 Stsciences, Inc. Anticorps spécifiques au btla glycosylé (atténuateur de lymphocytes b et t)
EP3383911B1 (fr) 2015-12-02 2021-01-20 STCube & Co. Inc. Anticorps et molécules se liant de manière immunospécifique à btn1a1 et leurs utilisations thérapeutiques
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
WO2018217528A1 (fr) 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Nanoparticules ultra-petites marquées avec du zirconium-89 et leurs procédés
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
RU2667906C1 (ru) * 2017-09-11 2018-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Производное класса N-гликозидов индоло[2,3-а]пирроло[3,4-с]карбазол-5,7-дионов - N-{ 12-(β-D-ксилопиранозил)-5,7-диоксо-индоло[2,3-а]пирроло[3,4-с] карбазол-6-ил} пиридин-2-карбоксамид, обладающее цитотоксической и противоопухолевой активностью
WO2019073069A1 (fr) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Anticorps humains dirigés contre l'antigène thomsen-nouveau (tn)
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4923986A (en) † 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
AU679752B2 (en) * 1993-05-28 1997-07-10 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
WO1995024190A2 (fr) * 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
SE506019C2 (sv) * 1994-05-17 1997-11-03 Forskarpatent I Linkoeping Ab Ljuskälla av konjugerade polymerer med spänningsstyrd färg samt metod för tillverkning av ljuskällan
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5659407A (en) * 1995-06-06 1997-08-19 Apple Computer, Inc. Method and system for rendering achromatic image data for image output devices
US6211215B1 (en) † 1996-07-19 2001-04-03 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
DK1011648T3 (da) 2001-12-27
CN1268061A (zh) 2000-09-27
NO20000732L (no) 2000-03-28
ES2163293T3 (es) 2002-01-16
BR9812122A (pt) 2000-07-18
PL193375B1 (pl) 2007-02-28
UA61970C2 (en) 2003-12-15
DE69802422T2 (de) 2002-07-11
HUP0003194A2 (hu) 2001-07-30
CA2299471A1 (fr) 1999-02-25
WO1999008668A2 (fr) 1999-02-25
EA002525B1 (ru) 2002-06-27
ATE208210T1 (de) 2001-11-15
EA200000220A1 (ru) 2000-10-30
CZ2000469A3 (cs) 2001-08-15
HUP0003194A3 (en) 2003-03-28
EP1011648B2 (fr) 2005-07-20
EP1011648B1 (fr) 2001-11-07
DE69802422D1 (de) 2001-12-13
US5985877A (en) 1999-11-16
NO20000732D0 (no) 2000-02-14
PL338885A1 (en) 2000-11-20
NO325526B1 (no) 2008-06-02
TR200000415T2 (tr) 2000-08-21
CZ297198B6 (cs) 2006-09-13
HK1028565A1 (en) 2001-02-23
ES2163293T5 (es) 2006-01-16
AU9019298A (en) 1999-03-08
EP1011648A2 (fr) 2000-06-28
DE69802422T3 (de) 2005-12-29
WO1999008668A3 (fr) 1999-04-15
NZ517497A (en) 2004-11-26
KR100612161B1 (ko) 2006-08-14
AU737092B2 (en) 2001-08-09
CN1147317C (zh) 2004-04-28
JP2001515032A (ja) 2001-09-18
CA2299471C (fr) 2007-12-18
PT1011648E (pt) 2002-03-28
NZ502646A (en) 2002-04-26
KR20010022878A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
DK1011648T3 (da) Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer
ATE368466T1 (de) Androgensyntheseinhibitoren
ATE399007T1 (de) Raf kinase hemmer
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
MY121548A (en) Compounds and methods for the treatment of cancer
DE69815313D1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
MD1616G2 (ro) Compuşi triciclici şi metodă de inhibare a receptorului tirozin kinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitului şi tratament al mamiferelor
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
ATE361075T1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
IL129705A (en) Use of selected benzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of uv radiation
EA199900914A1 (ru) Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена
DK0891344T3 (da) Antagonister til alpha-1-adrenergisk receptor
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
NO975838L (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.
ITMI920850A0 (it) Benzofurano-imidazoli per uso come inibitori di aromatisie 17,20-liasinella rpofilassi e trattamento del cancro della mammella e nell'iper- plasia prostatica benigna